Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2011 Dec 27;132(3):1063–1072. doi: 10.1007/s10549-011-1928-x

Figure 2. Treatment with VS induces in vivo hyper-acetylation of histone and non-histone proteins in ER-positive and ER-negative breast cancer cells.

Figure 2

Tumor biopsy specimens were collected from ER positive (#001, #010, and #53) and ER-negative (#51, 52, 54, and 55) patients prior to treatment with VS. Four hours following the third dose of VS, on Day 2, a second tumor biopsy was collected and cell lysates were prepared. Immunoblot analyses were performed for acetylated lysine, acetylated α-tubulin, acetylated K56 histone H3, acetylated histone H3, acetylated histone H4, p27 and p21 on the tumor cell lysates. The expression levels of β-actin in the lysates served as the loading control.